{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 128 of 129', 'Section no. and', 'Description of change', 'Brief rationale', 'name', 'Throughout', 'Minor editorial and document formatting revisions.', 'Minor, have therefore not', 'been summarised.', 'Amendment 1 (15-Dec-2017)', 'This amendment is considered to be non-substantial based on the criteria set forth in Article', '10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European', 'Union or subsequent regulation because it neither significantly impacts the safety or', 'physical/mental integrity of subjects nor the scientific value of the study.', 'Overall rationale for the amendment', 'The reason for the amendment is an operational change related to the non-investigational', 'medicinal product (TCS) to be handed out to the subjects. The need for this change was', 'identified after finalisation of the original protocol.', 'Note: The table below describes the changes in each section. Changes have either been', 'summarised (written with plain text only) or marked as tracked changes (text added to the', 'protocol is written in bold and deleted text has a line through it).', 'Section no. and', 'Description of change', 'Brief rationale', 'name', 'Protocol synopsis', 'ClinicalTrials.go identifier', 'As the identifier has become', 'Section 2', '(NCT03363854) added.', 'available since the time of', 'Trial identification', 'protocol finalisation.', 'Protocol synopsis', 'The mometasone furoate 0.1%', 'To provide flexibility across', 'Section 9.1.2', 'cream will be provided in kit sizes', 'regions due to differences in the', 'Non-investigational', 'of 180-225 g (instead of 200 g)', 'available pack sizes of', 'medicinal product', 'every 2 weeks.', 'mometasone furoate (0.1%', 'cream).', 'Section 9.1.3.2', 'Administration of', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 129 of 129', 'Section no. and', 'Description of change', 'Brief rationale', 'name', 'NIMP', 'Section 9.8.1.2', 'Labelling and', 'packaging of NIMP', 'Section 8.2', 'The subjects must have used the', 'Clarification that female', 'Inclusion criteria', 'contraceptive method continuously', 'subjects of childbearing', '(no. 11)', 'for at least 1 month prior to the', 'potential must have used a', 'pregnancy test at baseline.', 'highly effective form of birth', 'control for at least 1 month', 'prior to baseline.', 'Section 11.3.2', 'For the NIMP (mometasone furoate,', 'Specification that mometasone', 'LEO reporting', '0.1% cream) the latest version of', 'furoate will be supplied as 0.1%', 'responsibilities', 'the approved label must be used', 'cream. Details regarding the', '(see the Elocon\u00ae Summary of', 'approved labels have been', 'Product Characteristies [Europe],', 'omitted.', 'December 2015 edition and', 'subsequent updates; the Elocon\u00ae', 'Prescribing Information [USA],', 'April 2013 edition and subsequent', 'updates; or the Elocom\u00ae Product', 'Monograph [Canada], May 2014', 'edition and subsequent updates).', 'Section 11.5.6', 'Any clinically significant', 'Clarification that AE reporting', 'Aggravation of', 'aggravation/exacerbation/worsening', 'starts at screening, not baseline.', 'condition', 'of any medical condition(s)', 'This is in alignment with the', 'compared to baseline-screening,', 'information given in', 'must be reported as an AE.', 'Section 11.1 and Appendix 3D.', 'TMF-000005673 - Version 4.0']['Signature Page for TMF-000005673 v4.0', 'Reason for signing: Approved', 'Manage', 'Verdict(s)', 'Name: PPD', 'Capacit', 'Date of signature: 29-Aug-2018 20:22:18', 'GMT+0000', 'Reason for signing: Approved', 'Manage', 'ver Verdict(s)', 'Name: PPD', 'Capacil', 'Date of signature: 30-Aug-2018 09:14:53', 'GMT+0000', 'Reason for signing: Approved', 'Manage', 's)', 'Name: PPD', 'Capacil', 'Date of signature: 31-Aug-2018 05:51:34', 'GMT+0000', 'Electronic signatures made within eTMF LEO are considered to be a', 'legally binding equivalent of traditional handwritten signatures.', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}